Palvella Therapeutics (PVLA) Other Gross PP&E Adjustments (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$960000.0 as the latest value for Q4 2023.
- On a quarterly basis, Other Gross PP&E Adjustments fell 104.19% to -$960000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$960000.0, a N/A change, with the full-year FY2023 number at -$960000.0, down 104.19% from a year prior.
- Other Gross PP&E Adjustments was -$960000.0 for Q4 2023 at Palvella Therapeutics, down from $22.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $23.9 million in Q4 2020 to a low of -$960000.0 in Q4 2023.
- A 5-year average of $19.4 million and a median of $22.6 million in 2020 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 155.14% in 2020, then crashed 104.19% in 2023.
- Palvella Therapeutics' Other Gross PP&E Adjustments stood at $19.6 million in 2019, then increased by 21.87% to $23.9 million in 2020, then decreased by 4.17% to $22.9 million in 2021, then rose by 0.02% to $22.9 million in 2022, then plummeted by 104.19% to -$960000.0 in 2023.
- Per Business Quant, the three most recent readings for PVLA's Other Gross PP&E Adjustments are -$960000.0 (Q4 2023), $22.9 million (Q2 2023), and $22.9 million (Q1 2023).